Original Articles
EXPRESSION AND CLINICAL SIGNIFICANCE OF MULTIDRUG RESISTANCE GENE AND MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN GENE IN ACUTE LEUKEMIA
Abstract
Objective: To evaluate the expression and clinical significance of multidrug resistance gene (mdrl) and multidrug resistance-associated protein (MRP) gene in acute leukemia.
Methods: The expression of mdrl and MRP assay in 55 patients with acute leukemia (AL) by reverse transcription polymerase chain reaction (RT-PCR).
Results: The mdrl and MRP gene expression levels in the relapsed AL and the blastic plastic phases of CML were significantly higher than those in the newly diagnostic AL and controls. The mdrl and MRP gene expression levels in the clinical drug-resistant group were significantly higher than those in the non-drug-resistant group. The complete remission (CR) rate in patients with high mdrl expression (14.3%) was significantly lower than that with low mdrl expression (57.5%); similarly the CR rate in patients with high MRP level was also lower than that with low MRP level. Using both high expression of mdrl and MRP gene as the indicator for evaluating multidrug resistance (MDR), the positive predictive value and accuracy increased in comparison with single gene high expression.
Conclusion: Elevated level of mdrl or MRP gene expression might be unfavorable prognostic factors for AL patient and may be used as an important index for predicting drug-resistance and relapse in AL patient. Measuring both mdrl and MRP gene expression would increase accuracy and sensibility of evaluating MDR in acute leukemia.
Methods: The expression of mdrl and MRP assay in 55 patients with acute leukemia (AL) by reverse transcription polymerase chain reaction (RT-PCR).
Results: The mdrl and MRP gene expression levels in the relapsed AL and the blastic plastic phases of CML were significantly higher than those in the newly diagnostic AL and controls. The mdrl and MRP gene expression levels in the clinical drug-resistant group were significantly higher than those in the non-drug-resistant group. The complete remission (CR) rate in patients with high mdrl expression (14.3%) was significantly lower than that with low mdrl expression (57.5%); similarly the CR rate in patients with high MRP level was also lower than that with low MRP level. Using both high expression of mdrl and MRP gene as the indicator for evaluating multidrug resistance (MDR), the positive predictive value and accuracy increased in comparison with single gene high expression.
Conclusion: Elevated level of mdrl or MRP gene expression might be unfavorable prognostic factors for AL patient and may be used as an important index for predicting drug-resistance and relapse in AL patient. Measuring both mdrl and MRP gene expression would increase accuracy and sensibility of evaluating MDR in acute leukemia.
